TAMPERE CELIAC DISEASE SYMPOSIUM 2018
Serology and Biomarkers
September 13 - 15, 2018

University of Tampere, Faculty of Medicine and Life Sciences
Arvo Building, Arvo Ylpön katu 34, 33520 Tampere, Finland

Bus transportation from the city center to the symposium venue and back will be arranged.

Thursday, September 13, 2018

Satellite Symposium (no pre-registration required)
Thermo Fisher Scientific
Restaurant Ziberia, Address: Itäinenkatu 9, 33210 Tampere (Finlayson area, “next door” to the Symposium Get together at Restaurant Plevna)
Chair: Sune Sved, Thermo Fisher Scientific

17.30 - 18.00 Basis for good serology replacing biopsy in celiac disease clinical diagnostics
Markku Mäki, University of Tampere, Finland

18.00 - 18.30 Economical aspects of early celiac diagnosis
Katri Kaukinen, University of Tampere, Finland

18.30 - 18.50 Discussion

19.00 ‡ Tampere Celiac Disease Symposium 2018 Get together at Restaurant Plevna, address Itäinenkatu 8 (Finlayson area)

Friday, September 14, 2018

1. Opening session, Chair: Markku Mäki, Jarmo Visakorpi Auditorium, OPEN FOR ALL

09.00 - 09.10 Opening words
Markku Mäki, University of Tampere, Finland

09.10 - 09.20 3rd Maki Celiac Disease Tampere Prize announcement
Vice rector Seppo Parkkila, University of Tampere, Finland

09.20 - 09.50 Keynote lecture
Awardee

09.50 - 10.20 Keynote lecture
T- and B-cell involvement in celiac disease pathogenesis
Ludvig Sollid, University of Oslo, Norway

10.20 - 10.50 Coffee break and poster viewing, Yellow Hall
2. Use of serology biomarkers in celiac disease diagnosis and follow-up, Auditorium F114
Chair: Katri Kaukinen, Govind Makharia

10.50 - 11.15 Serum autoantibody testing in children
Sibylle Koletzko, University of Munich, Germany

11.15 - 11.40 Serum autoantibody testing in adults
Umberto Volta, University of Bologna, Italy

11.40 - 12.05 Pitfalls in serum autoantibody performance and interpretation
Ilma Korponay-Szabo, University of Debrecen, Hungary

12.05 - 12.25 Oral presentations (2)

12.25 - 13.30 Lunch break and poster viewing, Yellow Hall

3. Pathogenesis and biomarkers, Auditorium F114
Chair: Katri Lindfors, Ludvig Sollid

13.30 - 13.55 Mechanisms underlying development of inflammatory immune responses to dietary antigens
Bana Jabri, University of Chicago, USA

13.55 - 14.20 T- and B-cell immunology biomarkers
Robert Anderson, ImmusanT, USA

14.20 - 14.50 Oral presentations (3)

14.50 - 15.20 Coffee break and poster viewing, Yellow Hall

4. Genetic and non-immunological biomarkers, Auditorium F114
Chair: Keijo Viiri, Bana Jabri

15.20 - 15.45 Celiac disease genetics and biomarkers
Cisca Wijmenga, University of Groningen, The Netherlands

15.45 - 16.10 Non-immunological biomarkers in celiac disease
Govind Makharia, AIIMS, India

16.10 - 16.35 Keynote lecture
Imaging the unimaginable with Imaging mass cytometry
Frits Koning, University of Leiden, The Netherlands

16.35 - 17.00 Keynote lecture
Why and where to find surrogate biomarkers
Chaitan Khosla, Stanford University, USA

17.05 - 17.15 Oral presentation (1)

17.15 - 18.30 Poster rounds, wine and cheese, Yellow Hall

20.00 Dinner at Finlayson Palace, address Kuninkaankatu 1
Saturday, September 15, 2018

5. Biopsy in celiac disease clinics, needed or not?, Auditorium F114
Chair: Ilma Korponay-Szabo, Umberto Volta

09.00 - 09.25 Biopsy is the gold standard
Knut Lundin, University of Oslo, Norway

09.25 - 09.50 Serology-based diagnosis is the future
Katri Kaukinen, University of Tampere, Finland

09.50 - 10.20 Oral presentations (3)

10.20 - 10.50 Coffee break and poster viewing, Yellow Hall

6. The Finnish Celiac Disease Guidelines, Auditorium F114
Chair: Pekka Collin, Sibylle Koletzko

10.50 - 11.15 20-year anniversary of the Finnish Celiac Disease Guidelines.
Management model for 2018
Kalle Kurppa, University of Tampere, Finland

Panel Chair: Katri Kaukinen, Kalle Kurppa, Knut Lundin, Govind Makharia, Sibylle Koletzko
11.15 - 12.45 Panel and general discussion on “biopsy or not”
Invited commentaries

12.45 - 13.00 Best Abstract of the Symposium Prize, Kalle Kurppa, University of Tampere, Finland
Closing words, Markku Mäki, University of Tampere, Finland

13.00 Farewell lunch

Sponsored by:

ThermoFisher Scientific
EliA™ Celikey (tTG) and EliA GliadinDP – safe, efficient and automated assistance in identifying celiac disease patients

Innovate Biopharma is a clinical stage biotechnology company focused on developing novel medicines for autoimmune/inflammatory diseases. Innovate's celiac disease drug will enter Phase 3 clinical trials in the U.S. in 2018.
Developing therapeutic vaccine, Nexvax2, an antigen-specific immunotherapy for Celiac Disease. Planning for phase 2 study to start early 2018 in HLA DQ2.5 positive CeD patients who have been managed with gluten-free diet. Developing a highly specific and sensitive, simple blood-based diagnostic test: global studies to start early 2018.

For more information visit www.immusant.com

ImmunogenX is a clinical-stage company developing a therapeutic drug, latiglutenase, for the relief of symptoms in celiac disease patients and a minimally-invasive diagnostic technology, CypCel, for monitoring the state of villous health.

Biomedal has launched the first gluten consumption monitoring tests. Biomedal offers a range of last generation technology for detection of gluten. The gluten free diet monitoring can now be directly performed with Biomedal products for professional and at home use that can detect gluten in urine or stool samples with high sensitivity and specificity. Some of the clinical utility of those tests could be the immediate feedback for newly diagnosed celiacs to learn diet, the reassurance and confirmation about dietary compliance, monitoring of cumulative gluten consumption or to verify gluten challenge prior to diagnosis. For more information visit www.biomedal.com or contact info@biomedal.com
Probably the Best - since 1985.
Your Expert Partner in Gluten-Free Bakery Goods